Global DNA Repair Drugs Report: Focus on PARP Inhibitors 2016-2026 - Myriad Genetics and Foundation Medicine Have Emerged as the Major Diagnostic Developers - Research and Markets
DUBLIN, June 22, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "DNA Repair Drugs: Focus on PARP Inhibitors, 2016-2026" report to their offering.
The DNA Repair Drugs: Focus on PARP Inhibitors, 2016-2026 report is an elaborate study of drugs targeting DNA damage and repair systems, particularly, the enzyme PARP. DNA, the repository of genetic information, is susceptible to damage caused by several environmental and synthetic agents.
DNA damage leads to the incorporation of defects and aberrations in the genome that often result in functional mutations. When these mutations occur in genes coding for vital proteins and/or enzymes, it leads to the development of genetic diseases. However, our biological system is equipped with a robust repair mechanism capable of correcting damaged DNA sequences. PARP inhibitors and other similar therapeutics are designed to augment the body's innate DNA repair mechanism and aid in the treatment of diseases associated with genetic aberrations.
So far, this emerging class of drugs has only been evaluated across a niche population segment. This has led to increased efforts in the development of therapeutics targeting cells that harbor defects in their repair systems. There are several targets, other than PARP, that are also under clinical evaluation.
The PARP inhibitors market consists of a thin but promising pipeline of products targeting various indications. Since its serendipitous discovery, the developmental history of these candidate therapeutics has been full of ups and downs. The recalling of the late stage molecule, iniparib, and the termination of several other candidate therapeutics significantly impacted the growth of this segment of the industry. However, it has picked up pace after the commercialization of LynparzaTM (olaparib), the only marketed PARP inhibitor till date.
It is important to highlight the role of companion diagnostics, which have significantly contributed to growth in this segment. These molecular tools enabled therapy developers to accurately identify eligible patient groups. Encouraging clinical results demonstrating prolonged PFS and overall survival rates have also accelerated the progress of this drug class.
One of the key objectives of this study was to review and quantify the opportunities laid by the academia/industry players involved in this space. Considering the success of olaparib and clinical data from other active late stage development programs, we have presented an opinion on the anticipated success of PARP inhibitors.
Example Highlights
- Overall, we have identified 11 unique PARP inhibitors under clinical/preclinical development; of these, eight (73%) are being developed for oncological indications, two (18%) are under development for stroke and one (9%) is being developed for smoke inhalation injury and primary graft dysfunction.
- Four drugs are in late phase (phase III) of development; veliparib (AbbVie), talazoparib (Medivation), niraparib (Tesaro) and rucaparib (Clovis Oncology).
- Myriad Genetics and Foundation Medicine have emerged as the major diagnostic developers to actively join hands with PARP inhibitor developers. A companion diagnostic kit called BRACAnalysis CDx®, developed by Myriad Genetics, has been approved to be used with olaparib to detect mutations in the BRCA genes.
- We anticipate the PARP inhibitors market to grow aggressively at a healthy annual growth rate of 42% between 2016 and 2026. In the longer term, we expect the market to continue to rise steadily with high adoption rates of marketed drugs and approval of new drugs and indications.
- The overall opportunity will certainly face credible competition from several other classes of DNA repair inhibitors that are currently under development. Some prominent examples include APE inhibitors, nucleotide excision repair (NER) pathway inhibitors, O(6)-methylguanine-DNA methyltransferase (MGMT) inhibitors, DNA-protein kinase (DNA-PK) inhibitors, histone deacetylase (HDAC) inhibitors, cyclin dependent kinase (CDK) inhibitors and checkpoint kinase (CHK1) inhibitors.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Dna Damage And Repair Systems
4. Poly Adp-Ribose Polymerase Inhibitors
5. History Of Development
6. Market Landscape
7. Drug Profiles
8. Market Forecast
9. Publication Analysis
10. Competing Classes
11. Conclusion
12. Appendix I: Tabulated Data
13. Appendix II: List Of Companies And Organizations
Companies Mentioned - 35 of the 150+ Companies
- 4SC AG
- ARCAGY/ GINECO GROUP
- AbbVie
- Agouron Pharmaceuticals
- Almac Group
- American Association for Cancer Research
- American Society of Clinical Oncology
- Array BioPharma
- Ascopharm Groupe Novasco
- Astellas
- Astex Pharmaceuticals
- AstraZeneca
- BeiGene
- Beijing Cancer Hospital
- Beth Israel Deaconess Medical Center
- BiPar Sciences
- BioMarin Pharmaceuticals
- Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet
- Breast Cancer Research Foundation
- Breast International Group
- Bristol Myers Squibb
- British Columbia Cancer Agency
- Cambridge University Hospitals NHS Foundation Trust
- Cancer Research UK
- Cedars-Sinai Medical Center
- Celgene
- Cephalon
- Checkpoint Therapeutics
- ChemPartners (Service unit of ShangPharma)
- Christie Hospital NHS Foundation Trust
- Clovis Oncology
- Cooperative Ovarian Cancer Group for Immunotherapy
- Cyclacel Pharmaceuticals
- Cyteir Therapeutics
- Dana-Farber Cancer Institute
For more information visit http://www.researchandmarkets.com/research/3jhrv4/dna_repair_drugs
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Share this article